2Hideshlma T, Raje N, Richardson PG,et al. A review oflenalidomide in combination with dexamethasone for thetreatment of multiple myeloma[J].Ther Clin Risk Manag,2008,4(1):129-136.
2Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med, 2004, 351: 1860-1873.
3Rajkumar SV, Kyle RA. Multiple myeloma: Diagnosis and treatment. Mayo Clin Proc, 2005, 80: 1371-1382.
4Richardson P, Mitsiades C, Schlossman R, et al. The treatment of relapsed and refractory multiple myeloma. Hematology Am Soc Hematol Educ Program, 2007: 317-323.
5Hideshima T, Raje N, Richardson PG, et al. A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma. Ther Clin Risk Manag, 2008, 4(1): 129-136.
6Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 2002, 100: 3063- 3067.
7Richardson P, Jagannath S, Hussein M, et al. A multicenter, singlearm,open-label study to evaluate the efficacy and safety of singleagent lenalidomide in patients with relapsed and refractory multiple myeloma; preliminary results. Blood, 2005, 106: 449a.
8Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, 108: 3458-3464.
9Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America. N Engl J Med, 2007, 357: 2133-2142.
10Dimopoulos MA, Spencer A, Attal M, et al. Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma. N Engl J Med, 2007, 357: 2123-2132.
